Transforaminal 5% phenol neurolysis for the treatment of intractable cancer pain

Anesthesia and Analgesia

Volumn 110, Issue 1, 2010, Pages 216-219

  Candido, Kenneth D ^a   Philip, Cyril N ^a   Ghaly, Ramsis F ^a   Knezevic, Nebojsa Nick ^a  

^a ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DEXAMETHASONE; FENTANYL; GABAPENTIN; HYDROMORPHONE; IOPAMIDOL; LIDOCAINE; METHOCARBAMOL; PHENOL; NARCOTIC ANALGESIC AGENT; PHENOL DERIVATIVE;

ABSENCE OF SIDE EFFECTS; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DECOMPRESSION SURGERY; DRUG WITHDRAWAL; HUMAN; INTRACTABLE PAIN; LAMINECTOMY; LEIOMYOSARCOMA; LUMBAR VERTEBRA; MALE; METASTASIS; NEUROLYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SPINAL CORD TUMOR; VERTEBRA; PALLIATIVE THERAPY; PATHOLOGY;

AGED; ANALGESICS, OPIOID; HUMANS; LEIOMYOSARCOMA; MALE; NEOPLASM METASTASIS; PAIN, INTRACTABLE; PALLIATIVE CARE; PHENOLS; SPINAL NEOPLASMS;

EID: 74049156294     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181c0ecd5     Document Type: Article

References (27)

1. Keefe FJ, Abernethy AP, Campbell LC. Psychological approaches to understanding and treating disease-related pain. Annu Rev Psychol 2005;56:601-630
2. Portenoy RK. Cancer pain. Epidemiology and syndromes. Cancer 1989;63:2298-2307
3. Christo PJ, Mazloomdoost D. Cancer pain and analgesia. Ann NY Acad Sci 2008;1138:278-298
4. WHO. Cancer pain relief and palliative care: report of a WHO Expert Committee. Geneva: WHO, 1990
5. Sloan PA. The evolving role of interventional pain management in oncology. J Support Oncol 2004;2:491-500
6. Fine PG, Miaskowski C, Paice JA. Meeting the challenges in cancer pain management. J Support Oncol 2004;2:5-22
7. Higginson IJ, Hearn J. A multicenter evaluation of cancer pain control by palliative care teams. J Pain Symptom Manage 1997;14:29-35
8. Christo PJ, Mazloomdoost D. Interventional pain treatments for cancer pain. Ann NY Acad Sci 2008;1138:299-328
9. Candido K, Stevens RA. Intrathecal neurolytic blocks for the relief of cancer pain. Best Pract Res Clin Anaesthesiol 2003;17:407-428
10. de Leon-Casasola OA. Critical evaluation of chemical neurolysis of the sympathetic axis for cancer pain. Cancer Control 2000;7:142-148
11. Tolle SW, Tilden VP, Rosenfeld AG, Hickman SE. Family reports of barriers to optimal care of the dying. Nurs Res 2000;49:310-317
12. Brescia FJ. Pain management issues as part of the comprehensive care of the cancer patient. Semin Oncol 1993;20:48-52
13. Portenoy RK. Cancer pain: pathophysiology and syndromes. Lancet 1992;339:1026-1031
14. Ferrell BR, Wisdom C, Wenzl C. Quality of life as an outcome variable in the management of cancer pain. Cancer 1989;63:2321-2327
15. Yeager MP, Colacchio TA, Yu CT, Hildebrandt L, Howell AL, Weiss J, Guyre PM. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 1995;83:500-508
16. Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, Sauter PK. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg 1993;217:447-455
17. Patt RB. Cancer pain. Philadelphia, PA: JB Lippincott, 1993
18. Lifshitz S, Debacker LJ, Buchsbaum HJ. Subarachnoid phenol block for pain relief in gynecologic malignancy. Obstet Gynecol 1976;48:316-320
19. Plancarte R, de Leon-Casasola OA, El-Helaly M, Allende S, Lema MJ. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth 1997;22:562-568
20. Slatkin NE, Rhiner M. Phenol saddle blocks for intractable pain at end of life: report of four cases and literature review. Am J Hosp Palliat Care 2003;20:62-66
21. Turker G, Basagan-Mogol E, Gurbet A, Ozturk C, Uckunkaya N, Sahin S. A new technique for superior hypogastric plexus block: the posteromedian transdiscal approach. Tohoku J Exp Med 2005;206:277-281
22. ASA. Practice guidelines for chronic pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management, Chronic Pain Section. Anesthesiology 1997; 86:995-1004
23. Weksler N, Klein M, Gurevitch B, Rozentsveig V, Rudich Z, Brill S, Lottan M. Phenol neurolysis for severe chronic nonmalignant pain: is the old also obsolete? Pain Med 2007;8:332-337
24. Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil 1998;77:510-515
25. Superville-Sovak B, Rasminsky M, Finlayson MH. Complications of phenol neuroloysis. Arch Neurol 1975;32:226-228
26. Galizia EJ, Lahiri SK. Paraplegia following coeliac plexus block with phenol. Case report. Br J Anaesth 1974;46:539-540
27. Kowalewski R, Schurch B, Hodler J, Borgeat A. Persistent paraplegia after an aqueous 7.5% phenol solution to the anterior motor root for intercostal neurolysis: a case report. Arch Phys Med Rehabil 2002;83:283-285